Among them, IL-6 secreted by CAFs can reduce the response of cancer cells to chemotherapeutics (106, 107), and stromal cell-derived factor-1 (SDF-1) secreted by CAFs (108) can stimulate the malignant progression of pancreatic cancer and mediate the development of gemcitabine resistance. Here, CXCL12 is linked to pancreatic neoplasm.